Why Amdocs is a high conviction Buy for me?

As a quantitative fundamental value investor, I seek out for deep value stocks, estimate their fair value, compute their intrinsic price and run them through my check list to see if I can invest in them. I take the three filter approach for this - is my thesis

• Possible?
• Plausible?
• Probable?

The criteria I use to translate the 3 Ps is as follows:

The rest of this narrative explore the 3Ps and while doing it provide some context on why Amdocs is a high conviction buy for me despite the stock declining by almost 50% in the last year or so.

Amocs - Qualitative Overview

At the heart of its operations, Amdocs serves as a critical bridge between legacy infrastructure and modern digital requirements, supporting complex telco IT environments with a focus on business support systems (BSS) and operations support systems (OSS). With a deep, long-standing domain expertise that the company describes as its "native language," Amdocs is currently evolving from its traditional service-provider roots into a GenAI-native transformation specialist.

Financially, the company is characterized by strong recurring revenue streams, highlighted by a high renewal rate for managed services—which account for approximately 65% of total revenue—and a substantial 12-month backlog of $4.28 billion. This stability allows the company to pursue a disciplined capital allocation strategy, featuring consistent dividend growth and significant share repurchases. As the industry shifts toward cloud-native architectures, Amdocs is leveraging its aOS (agentic operating system) and amAIz frameworks to drive modernization, positioning itself as a vital architect of the next generation of connectivity services.

• Dominant Market Position: Amdocs maintains a 14% global market share in telco IT software and has held a leadership position in monetization platforms for 17 consecutive years.
• Strong Recurring Revenue: The business is supported by a stable, recurring revenue model, with managed services accounting for approximately 65% of total revenue and maintaining renewal rates near 100%.
• Backlog and Stability: The company’s operational stability is bolstered by a substantial 12-month backlog of $4.28 billion.
• Capital Allocation: Amdocs pursues a disciplined strategy of returning capital to shareholders through consistent dividend growth—now spanning 14 consecutive years—and active share repurchases.
• Strategic Evolution: The company is currently transitioning its focus from traditional OSS/BSS support toward GenAI-native transformation, utilizing its aOS (agentic operating system) and amAIz frameworks to modernize client applications.

Fundamentals

From Simply Wall Street's overview page, Amdocs is currently trading at a PE of 10.2 , compared to the peer group average of 27.7, operating at a net margin of 12% and Return of Equity of 16%. The balance sheet is reasonably strong with Debt to Equity sitting at 26% and the Interest Coverage sitting of 30X. These numbers, while unremarkable, are definitely healthy. What makes Amdocs compelling is the recent market reaction to the AI disruption fears.

The 3P evaluation for Amdocs - Is it Possible?

In order to test my first filter - is it possible for me to even consider Amdocs - I want to ensure the market price is less than its intrinsic value and intrinsic price. To me, intrinsic value is based on Future Cash Flows, Growth, and Operating Risk and I estimate it using a Discounted Cash Flow Model. My estimate of Amdocs' intrinsic value is $82.03

Intrinsic price is an estimate of the market price of the stock if it were to be treated like a bond whose coupon value is the dividend it pays. In order to ensure I price it fully, I consider the potential dividend, not what the firm pays actually. To me, the potential dividend is Free Cash Flow to Equity investors. Expected rate of return would be the cost of equity for Amdocs after accounting for its risk and the risk free rate an investor can expect such as the 10 year treasury bond rate. I then use a modified version of the Gordon Growth Equation to estimate the intrinsic price.

Based on the above table, the intrinsic price of Amdocs is $74.93

The 3P evaluation for Amdocs - Is it Plausible?

In order to test my second filter, I run a Monte Carlo simulation using growth and margin estimates with distributions of growth and margin since I’m uncertain, and run 10,000 different scenarios to see what is my Margin of Safety (the probability mass between the market price and fair value estimate) and the relative discount between the market price and the intrinsic price

The 3P evaluation for Amdocs - Is it Probable?

The last filter is to check if the thesis is likely to happen or not. To understand this, I return to my Monte Carlo engine again to check the under value thesis' probability - the probability mass to the right of the market price in the figure above, and also check for the conditional probability of the market price being lower than the intrinsic price, given the stock is undervalued. Lastly, I check if there is runway for me to achieve capital growth. The synthesis of all these three gates is prsented in the table below:

Conclusion

No one can predict what will happen to the stock in in this debt driven AI rally that is increasingly reminding me of the dotcom era but I return to my table to ensure I'm not blindsided by the vagaries of the market. It is my port of safety when the water becomes choppy. I remain convinced that Amdocs is a good buy based on my 3Ps framework.